A numerical imbalance in deaths in Esperion Therapeutics Inc.'s long-term safety study for the cholesterol-lowering drug bempedoic acid is raising concerns about competitive positioning and ability to file prior to having cardiovascular outcomes data, which could delay the product's launch.
Bempedoic acid is a first-in-class inhibitor of ATP citrate lyase (ACL) that upregulates the LDL-C receptor in order to reduce...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)